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ABSTRACT
Although the role of the APOBEC3-dependent retro-
element restriction system as an intrinsic immune
defense against human immunodeficiency virus
type1 (HIV-1) infection is becoming clear, only the
rat ortholog of mammalian APOBEC1s (A1) thus
far has been shown to possess antiviral activity.
Here, we cloned A1 cDNAs from small animal spe-
cies, and showed that similar to rat A1, both wild-
type and "vif HIV-1 infection was inhibited by mouse
and hamster A1 (4- to 10-fold), whereas human A1
had negligible effects. Moreover, rabbit A1 signifi-
cantly reduced the infectivity of both HIV-1 virions
(`300-fold), as well as that of SIVmac, SIVagm, FIV
and murine leukemia virus. Immunoblot analysis
showed that A1s were efficiently incorporated into
the HIV-1 virion, and their packaging is mediated
through an interaction with the nucleocapsid Gag
domain. Interestingly, there was a clear accumula-
tion of particular C-T changes in the genomic RNAs
of HIV-1 produced in their presence, with few G-A
changes in the proviral DNA. Together, these data
reveal that A1 may function as a defense mechan-
ism, regulating retroelements in a wide range of
mammalian species.
INTRODUCTION
It is now clear that the scope of intracellular defense
mechanisms against retroviral infections extend beyond
the conventional innate and acquired immune responses,
involving a series of dominant inhibitory activities that
inﬂuence retroviral tropism. Two major restriction factors
identiﬁed thus far are the early block owing to Fv1 and
TRIM5a that target incoming retroviral capsids, and cyti-
dine deaminases, such as APOBEC3 (A3) that function at
the late phase to hypermutate retroviral genome (1). The
A3 proteins have been shown to inhibit the infectivity
potential and mobility of a broad and growing number
of exogenous retroviruses as well as endogenous retroele-
ments (2,3). A3 edits deoxycytidine (dC) to deoxyuridine
(dU) on nascent DNA minus strands during reverse tran-
scription, but the mechanisms underlying the inhibitory
eﬀect on retroviruses are not fully understood.
The A3encoded by mousegenome was found tobe about
 30% identical to the human APOBEC3G (hA3G), ini-
tially identiﬁed as a critical target for the human immuno-
deﬁciency virus type1 (HIV-1) auxiliary protein Vif (4,5).
Subsequently, anti-HIV activity of A3 was found to be
maintained across diverse mammalian species, such as
murine, cat and artiodactyls (cattle, pigs and sheep) in
spite of extensive amino acid sequence divergence, and
regardless of whether lentiviruses infect the species (5–8).
However, the interaction of Vif with A3 molecules is spe-
cies speciﬁc, and this Vif-resistant inhibition of HIV-1 by
orthologous A3 proteins appears to contribute to restrict
cells from nonprimate mammalian species to support
productive HIV-1 replication. Thus, the removal of the
A3-mediated block will be required for the development of
a small animal model in which HIV-1 replicates eﬃciently.
Although the role of the A3-dependent retroelement
restriction system as an intrinsic resistance mechanism is
becoming clear, less well understood is mammalian
APOBEC1 (A1), the catalytic component of a complex
that deaminates apolipoprotein B mRNA in gastrointest-
inal tissues (9,10). It has been also shown that A1 exhibit
potent DNA mutator activity in an Escherichia coli assay
(11). Rodent A1s share  70% amino acid sequence
identity with human A1, but only rat homolog of A1
was shown to restrict HIV-1 independent of Vif (12,13).
To address whether A1 orthologs are involved in an innate
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from small animal species were cloned, and expressed in
order to examine their abilities to inﬂuence the infectivities
of retroviral virions. Our studies show that several A1s from
small animal species were eﬃciently incorporated into the
HIV-1 virion via interaction with the nucleocapsid (NC)
Gag domain, and suppressed HIV-1 replication in a cyti-
dine deaminase dependent as well as independent manner.
Interestingly, there was a clear accumulation of particular
C-Tchanges inthegenomic RNAsproduced inthe presence
of rabbit A1, with few G-A changes in the proviral DNA.
Moreover, the local mutational preferences on HIV-1
genomic RNA were found to be similar to those observed
in apoB mRNA. Importantly, mutation of the catalytic
residue Glu63 signiﬁcantly reduced antiviral activity, and
diminished G-A or C-T changes. Further, these deaminases
also inhibited simian immunodeﬁciency virus (SIV)mac,
SIVagm and feline immunodeﬁciency virus (FIV) infec-
tions and to a lesser extent murine leukemia virus (MLV).
Together, these data reveal that, unlike their human coun-
terparts, A1 in a wide range of mammalian species may
function as a defense mechanism regulating retroelements.
MATERIALS AND METHODS
Molecular cloning ofA1s
Primary tissues were prepared from small intestines, which
had been removed aseptically from euthanatized ferret
(Mustela putorius furo), rabbit (Kbt: NZW), hamster (Slc:
Syrian) and mouse (C57BL/6N), respectively. Total RNA
was prepared using TRIzol reagent (Invitrogen, Carlsbad,
CA) and the synthesis of ﬁrst strand cDNA was carried out
withHighCapacitycDNAArchiveKit(AppliedBiosystems,
FosterCity,CA)usingarandomprimer.cDNAfromhuman
small intestineandrat(Sprague-Dawley)liverwaspurchased
from BD Biosciences Clontech, Palo Alto, CA (BD
TM
Marathon-ReadycDNA,Cat.#639326and#639413,respec-
tively). The cDNA encoding the entire openreading frame of
the A1 were ampliﬁed using primer sets designated as seen in
Table S1, based on A1 sequences from GeneBank except for
ferret. Taq polymerase-ampliﬁed PCR products were cloned
into pCR-Blunt (Invitrogen) vector and sequenced. The pri-
mary PCR product was subsequently reampliﬁed by using
oligonucleotides containing EcoRV and NotI cloning sites.
Antisense primers encoded the hemagglutinin (HA)-epitope
sequence YPYDVPDYA. Amplicons were cleaved at the
restriction sites and ligated to similarly cleaved pCAGGS
vector (14), yielding HA tagged A1 expression vectors.
pCAGGS-based expression plasmids for HA-tagged hA3G
has been described elsewhere (15). PCR products generated
and digested as described above were also inserted into
pcDNA 3.1/Zeo (Invitrogen).
Generationof catalytic site-mutated rabbit A1
expression vectors
Rabbit A1 catalytically inactive mutants E63A and E63Q
were constructed with QuickChange XL Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA) using oligo-
nucleotide primers (Table S1), and inserted into pCAGGS
vector.
Amino acid alignments and phylogenetic analysis
Protein sequences of full-length mammalian A1s were
aligned with Clustal W software. Phylogenetic trees were
reconstructed using the neighbor-joining method with
2000 bootstrap replications. MEGA 3.1 was used for
phylogenetic analysis. The GenBank accession numbers
of the A1 sequences used in these comparisons were rat
(NM012907), mouse (NM031159), human (NM001644),
opossum (NM001032982), rabbit (U10695), orangutan
(AH013823), chimpanzee (XM001164661), rhesus monkey
(XM001112583), cattle (XM594173), dog (XM543826),
hamster (AF176577) and horse (XM001493159). The
sequence of A1s reported in this article has been deposited
in the GenBank data base (accession number AB425821).
Viral preparation and infectivity assay
293T, GP293, HeLa, Caco-2 and Mus dunni tail ﬁbroblasts
(MDTF) cells were maintained in DMEM supplemented
with 10% fetal calf serum (Gibco, Grand Island, NY).
VSV-G pseudotyped HIV-1-based luciferase reporter virus
stocks were produced in 293T cells by cotransfection of
wild-type or Dvif pNL4-3 Luc E
 R
  (5), together with
pVSV-G and one of several expression vectors encoding
APOBEC proteins, which are HA-epitope tagged or a
control empty vector using Eﬀectene (Qiagen, Hilden,
Germany). Culture supernatants were harvested, ﬁltered
and frozen in aliquots. The p24 content of the viruses was
determined in ELISA kits (ZeptoMetrix, Buﬀalo, NY).
Target fresh 293T cells were infected with 0.5–1.5 ng equiv-
alent of luciferase reporter viruses and cultured for 48h.
Infected cells were lyzed, and each lysate was assayed for
luciferase activity as previously described (16). Single-round
SIVmac and SIVagm luciferase reportervirus stocks with or
without Vif were produced as VSV-G pseudotypes in 293T
cells by cotransfection of pSIV Luc E
 R
  or pSIV Luc
E
 R
  Dvif (5) and an expression vectors for APOBECs or
a mock vector. The p27 content of the viruses was deter-
mined in ELISA kits (ZeptoMetrix). Target fresh 293T cells
were infected for with 4.0–80 ng equivalent of luciferase
reporter viruses and cultured for 48h. Infected cells were
lyzed and each lysate was assayed for luciferase activity.
To generate FIV-GFP virus, 293T cells were transfected
with pFIV-H1/copGFP and pFIV-34N (System Bioscience,
Mountain View, CA), pVSV-G and APOBEC expression
vector or an empty vector. Culture supernatants were
ﬁltered and centrifuged at 40000g for 1h. Target cells
were infected with FIV-GFP viruses, equivalent to 8ng
of reverse transcriptase estimated by using Reverse
Transcriptase Assay (Roche, Basel, Switzerland) and
the infectivity was measured by ﬂow cytometry at 48h
postinfection. Single-round MLV reporter virus stocks
were produced as VSV-G pseudotypes in GP293 cells
expressing Moloney MLV gag and pol genes (17) by
cotransfection of pFB-Luc or pFB-hrGFP (Stratagene)
together with expression vectors for APOBECs or a
mock vector. Virus-containing supernatants were nor-
malized for equal MLV p30 CA content estimated by
Western analysis. Target MDTF cells were infected
with equivalent amounts of MLV reporter viruses and
cultured for 48h. Values are presented as the percent
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without the expression of APOBECs.
Editing ofHIV-1 proviral DNA and genomicRNA
The cells were harvested 48h postinfection, and total
DNA was isolated using the QIAamp DNA Blood Mini
Kit (Qiagen). A 408 bp of the HIV-1 pol region was ampli-
ﬁed with the high-ﬁdelity DNA polymerase (Takara,
Ohtsu, Japan) subsequent to the digestion with DpnI.
Ampliﬁed fragments were subsequently gel puriﬁed, then
cloned into pCR-Blunt vector (Invitrogen) and sequenced.
The viral genomic RNA in cell-free virions was puriﬁed
using QIAamp viral RNA Mini Kit (Qiagen) and con-
verted to cDNA in vitro using a High Capacity cDNA
Archive kit with random primers, sebsequent to the treat-
ment with DNase. The pol region was ampliﬁed by PCR,
cloned and sequenced as described above.
Western blot analysis
The encapsidation of APOBEC proteins into HIV-1 or
MLV virions were detected by pelleting the supernatant
of 293T cells transfected with viral DNA and HA-epitope
tagged forms of the APOBEC expression vector through a
20% sucrose cushion. The pellets were solubilized in 50ml
of 1% Triton-containing buﬀer and the equivalent p24 of
each solubilized virions was subjected to immunoblot
analysis. Cell lysates, virion lysates and immunoprecip-
itates were subjected to SDS–PAGE, and then trans-
ferred to a PVDF membrane (Millipore, Bedford, MA).
The membranes were probed with the anti-HA epitope
(HA.11; Covance, Princeton, NJ) or anti-b-actin (AC-74;
Sigma, Saint Louis, MO) antibody. A monoclonal anti-
body recognizing the p24 CA (18) and a goat anti-MLV
p30 serum (ViroMed Biosafety Labs, Camden, NJ) was
used for detection of HIV-1 and MLV CA, respectively.
Reactive proteins were detected using biotin-conjugated
rabbit immunoglobulin (Sigma), streptoavidin-conjugated
peroxidase (Sigma) and developed using Chemi-Lumi One
(Nacalai Tesque, Kyoto, Japan). The plasmids expressing
HIV-1 Gag or the deletion mutants were described pre-
viously (22). Bands in western blots were quantiﬁed on a
VersaDoc 5000 imager (BIO-RAD, Hercules, CA).
Nucleotide sequence accession numbers
The sequences determined in this study have been sub-
mitted to GenBank and assigned accession no. AB425821.
RESULTS
Molecular cloning and phylogenetic analysis of
mammalian A1s
We cloned, sequenced and compared the predicted amino
acid sequences of A1 cDNAs from primate (human), car-
nivora (ferret), lagomorphs (rabbit) and rodents (hamster,
rat, mouse). Sequence analysis revealed that the clones
obtained encoded genes that were identical to the
GenBank sequences of A1s (rabbit;U10695, hamster;
AF176577, rat;NM012907 and mouse;NM031159),
except for one amino acid residue (M80I) substitution in
human A1 (NM001644). Results showed that human A1
cDNA encodes an open reading frame of 236 amino acids
that has a 78.0% amino acid sequence identity with ferret,
75.8% with rabbit and 70–72% with rodent orthologs.
A short C-terminal extension was found in human and
rabbit as previously reported (19), and also in ferrets but
not in rodents. In particular, the active site motif, desig-
nated as His-X-Glu-(X)23-28-Pro-Cys-X2-Cys (X can be
any amino acid) (20), was well conserved (Figure 1A).
Phlyogenetic tree analyses revealed that the rabbit A1
gene is related to primate A1 genes, while A1s from
rodents form a single separate cluster (Figure 1B).
A1sfromsmallanimalspeciesinhibitHIV-1virioninfectivity
To examine the anti-HIV activities of A1s from these small
animal species, single-round infectivity assay with VSV-G
pseudotyped wild-type and Dvif HIV-1 luciferase reporter
viruses (5) produced in the presence of the inﬂuenza HA
epitope-tagged A1 proteins was performed. hA3G was
used as a control in these experiments. To examine the
eﬀect on HIV-1 infectivity quantitatively, virions were nor-
malized based on p24 content. Virus-induced intracellular
luciferase activity, which is directly proportional to the
infectivity of the virus, was measured 48h after infection
and calculated relative to the APOBEC-negative control
virus (Figure 2A, Mock). As expected, hA3G caused a
modest decrease in infectivity of the wild-type and a more
pronounced decrease in infectivity of the Dvif HIV-1virus
(Figure 2A). A1 from human intestine did not showed any
antiviral activity, while, in agreement with previous obser-
vations (12,13), A1 from rat caused a relatively small (2- to
3-fold) decrease in infectivity of the Dvif HIV-1virus and
a 45-fold decrease in infectivity of the wild-type virus
(Figure 2A). In contrast with previous ﬁndings however
(5,12,13), the A1s from rodents, such as hamster and
mouse were equally active against wild-type and Dvif
HIV-1 viruses, reducing their infectivity 41 0 - f o l di ns o m e
experiments. A modest reduction in infectivity of wild-type
and Dvif viruses was also found with A1 from ferrets, but of
more interest are the ﬁndings with A1 from rabbits. Over
100-fold decrease in the Dvif HIV-1 virus and a more pro-
nounced 300-fold decrease in infectivity of the wild-type
virus was seen with this cytidine deaminase from rabbits.
Identical results were obtained when rabbit A1 was
expressed with an alternate expression vector, pcDNA3.1
(Figure S1), ruling out an eﬀect speciﬁc to the pCAGGS
construct used in these experiments. Dose titration studies
showed that as little as 0.05mg of rabbit A1 was suﬃcient to
achieve signiﬁcant inhibition against HIV-1 (Figure 2B), 10-
to 20-fold more potent than APOBECs from other small
animal species. For further conﬁrmation, the anti-HIV
activity of A1s from small animal species was examined
with the use of a HIV-1-based the green ﬂuorescent protein
(GFP)-expressing reporter virus. As shown in Figure S2, the
results obtained with the HIV-GFP vector are consistent
with those seen using the HIV-Luc vector. These multiple
lines of investigations indicate that, similar to hA3G, A1s
from small animal species can function on HIV-1.
The cytidine deaminase domains of APOBEC proteins
contains an active site with conserved consensus motifs in
Nucleic Acids Research, 2008, Vol. 36, No. 21 6861which the His–Cys–Cys residues coordinate a Zn
2+ ion,
and the Glu residue serving an essential role in catalysis as
a proton shuttle (21). Therefore, we generated the catalytic
site mutant forms of rabbit A1 in which the critical Glu-63
of active site was changed to Ala or Gln (E63A, E63Q),
and examined their antiviral activity. Results showed that
the ability of the mutant proteins to restrict the infectivity
of wild-type and Dvif viruses were severely, but not com-
pletely impaired (Figure 2C), suggesting the existence of
an albeit weak deaminase-independent restriction mechan-
ism by A1.
A1s arepackaged into HIV-1 virions
It is now well established that human and murine
A3s inhibit HIV-1 infectivity by being packaged into
progeny virions. Therefore, we veriﬁed whether A1 pro-
teins (which are epitope tagged) would indeed be selec-
tively packaged into HIV-1 virions. For these studies,
transfected cells were harvested, and proteins in whole-
cell lysates were analyzed by western blotting with anti-
HA, anti-HIV-1 CA p24 and anti-b-actin monoclonal
antibodies with the b-actin blot serving as a loading con-
trol. Data showed comparable amounts of A1 proteins
and HIV-1 Gag precursor protein (p55) expression,
but minor eﬀects on the processing eﬃciency into p24
CA with some A1 proteins (e.g. human and rabbit,
Figure 2D). Cell-free virus was concentrated by pelleting
through a 20% sucrose cushion, and then equivalent
amount of solubilized virions was subjected into the wes-
tern blotting. A1 proteins from small animal species were
A 10 20 30 40  50 60 70 80  90  100 
....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|....|
Human MTSEKGPSTGDPTLRRRIEPWEFDVFYDPRELRKEACLLYEIKWGMSRKIWRSSGKNTTNHVEVNFIKKFTSERDFHPSISCSITWFLSWSPCWECSQA I
Ferret .A.D....A..A...........E..F...............Q..T.H.M..NT....A....L...E......RYC..TH................K..
Rabbit .A......NK.Y...........E..F..Q...............A.S.T................LE.L...GRLG..TC................M..
Hamster .S..T..VVV..........H...A.F.QG.....T......R..GRHN...HT.Q..SR...I...E......Y.Y..TR...V........G...K..
Rat .S..T..VAV..........H..E..F........T......N..GRHS...HTSQ..NK.......E...T..Y.C.NTR............G...R..
Mouse .S..T..VAV..........H..E..F........T......N..GRHSV..HTSQ..S.......LE...T..Y.R.NTR............G...R..
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Ferret .G...QC.S.......T.......P.........LK....VR....P..D...K........K.D...R..E...K..E...Y...............N .
Rabbit .....Q......I.F.....Q...RR.....K...T....VRV.SV...CY..E........KA.Q..R...R..LM.....Y....G..........H.
Hamster T....G..N...F..A...YH.T..R........ISR....R..TEQ..CY..........SN.VY..R..N...R......Y..H.G.......K..H.
Rat T.....Y.H...F..I...YH.A.PR........IS........TEQ.SGY........S.SN.....R..H..VR..V...Y....G.....N.L..K.
Mouse T.......Y...F..I...YH.T..R........IS........TEQ..CY..........SN..Y..R..H..VK..V...Y....G.......L..K.
210 220 230 
....|....|....|....|....|....|....|.. 
Human NHLTFFRLHLQNCHYQTIPPHILLATGLIHPSVAWR 236 a.a.
Ferret KQ..L...T.......I.......D....QLP.I.. 236 a.a.
Rabbit KQ....S.TP.Y...KM...Y.......LQ...P..  236 a.a.
Hamster YP......N..S....R......W...F.  229 a.a.
Rat PQ....TIA..S....RL.....W....K  229 a.a.
Mouse PQ....TIT..T....R....L.W....K  229 a.a.
B Human
Chimpanzee
Orangutan
Rhesus monkey
Rabbit
Ferret
Dog
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0. 1
Figure 1. Alignment of the amino acid sequence and phylogenetic analysis of mammalian A1 proteins. (A) Amino acid sequence alignment of A1
from human, ferret, rabbit, hamstar, rat and mouse. The predicted amino acid sequences of these cloned A1 molecules are aligned with Clustal W
software to the previously identiﬁed sequences of mammalian A1s. The numbers are amino acid residue positions. (B) Phylogenetic analysis of the
protein sequences of full-length mammalian A1s. The tree was reconstructed by neighbor-joining method with protein p-distances using MEGA 3.1.
Shown interior nodes are bootstrap percentages derived from 2000 replications. Branch lengths represent the number of substitution per site.
Opossum is a separate group. The species used for further experiments in this study are indicated in bold letters.
6862 Nucleic Acids Research, 2008, Vol. 36, No. 21found to be packaged into HIV-1 virions, but variations in
the eﬃciency of the incorporation of each A1 protein were
seen. Rabbit A1 was incorporated eﬃciently, which could
explain for its potent antiviral activity. The incorporations
into HIV-1 virions of A1s from small animal species were
not aﬀected by expression of the Vif protein (Figure 2D).
We therefore conclude that A1s like hA3G are speciﬁcally
packaged into HIV-1 virions. However, unlike hA3G, this
incorporation is not inhibited with coexpression of HIV-1
Vif. The mutant rabbit A1 E63A E63Q proteins were cor-
rectly expressed within the producer cells and also incor-
porated into the HIV-1 virions eﬃciently, as judged by
western blot analysis (data not shown).
The HIV-1 Gag NC domainis requiredfor A1packaging
We next determined whether parts of Gag were dispens-
able for A1 packaging into virions, by use of previously
described Gag mutants (22). Two Gag deletion mutants,
d10-110 mutant lacking residues 10 through 110, d10-277
mutant lacking residues 10 through 277 or the Zwt-p6
mutant, in which NC is replaced by a leucine zipper
from GCN4 were tested (Figure 3A). A1s from human,
rabbit and rat as well as hA3G were eﬃciently incor-
porated into virus like particles (VLPs) formed by both
Gag deletion d10-110 and d10-277 mutants (Figure 3B).
Consistent with previous observations (22), hA3G was
not incorporated into VLP formed by Zwt-p6 mutant.
A1 from human and rabbit did not exhibit any detectable
incorporation, while, A1 from rat caused a relatively small
amount of incorporation into VLP formed by Zwt-p6
mutant (Figure 3B). Thus, almost all matrix and the
amino-terminal two-thirds of capsid appear to be largely
dispensable for A1 packaging, similar to those observed
in hA3G packaging.
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Figure 2. Inhibition of HIV-1 infection by A1s. (A) VSV-G pseudotyped wild-type and Dvif HIV-1 luciferase viruses were produced in 293T cells
transfected with 1.5mg of luciferase reporter viruses, 1.0mg of pVSV-G and 0.5mg of HA-tagged APOBEC expression vector or empty vector. Virus-
containing supernatants were normalized for equal p24 content and used for the infection of the fresh 293T cells. Virus-induced intracellular luciferase
activity was measured. Data are presented as a percentage of the level of luciferase activity detected in cells infected with virions derived from cells that
did not express an exogenous APOBEC protein. The average of three experiments with standard deviation is indicated. (B) Wild-type and Dvif HIV-1
luciferase reporter viruses pseudotyped were produced in 293T cells transfected with decreasing amounts of HA-tagged APOBEC expression vector.
The amount of expression vector plasmid transfected is shown in micro gram on the X-axis. (C) The catalysis domain of A1 is required for the eﬃcient
anti-HIV-1 potency of the rabbit A1. The HA-tagged rabbit A1 (WT), A1 mutated in the active site motif (E63A and E63Q) were used. (D) A1 proteins
from small animal species are encapsidated into HIV-1 virions. The producer cells were collected and lyzed, while the released virus in the supernatants
were collected by ultracentrifugation. The cells and virion lysates were then subjected to Western analysis using an antibody speciﬁc for the HA tag and
HIV-1 Gag CA. The immunoblot probed with anti-b-actin antibody of the proteins present in the cell lysates is shown.
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Figure 3. A1 proteins are encapsidated into HIV-1 virions via through the interaction with NC, but not the majority of Gag. (A) Schematic
representation of the intact HIV-1 Gag precursor and its derivatives used in this study. The Gag are myristoylated (Myr-) on the N-tereminus of
MA. The positions of the major homology region (MHR) and the various Gag cleavage sites are shown. (B) Western blot analysis of cell lysates and
extracellular VLPs generated following transfection of 293T cells with plasmids expressing HIV-1 Gag or its derivatives shown in (A) and the
HA-epitope tagged forms of the indicated APOBEC proteins. The producer cells were collected and lyzed, while the supernatants were harvested and
released virus were collected by ultracentrifugation. The cells and virion lysates were then subjected to Western analysis using antibodies speciﬁc for
the HIV-1 Gag CA and HA tag. The immunoblot probed with anti-b-actin antibody of the proteins present in the cell lysates is shown. Results were
normalized to those obtained from the transfection of cells with the full-length Gag and APOBEC constructs, and were graphically shown as relative
packaging.
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A3-mediated antiretroviral activity has been shown to be
associated with cytidine deamination of nascently tran-
scribed viral cDNAs following infection of target cells.
Such dC-to-dU deamination in minus-strand DNA is
detected as replacement of dG-to-dA in integrated pro-
viral genomes. To address whether A1 functions in a simi-
lar manner, accumulation of dG-to-dA changes in the
proviral DNA during reversetranscription was examined.
Viral DNA was prepared from cells infected with wild-
type or Dvif HIV-1 viruses produced in the presence of
A1s from small animal species, and the 30-end of the pol
gene was analyzed for evidence of hypermutation.
Consistent with previous reports, signiﬁcant dG-to-dA
hypermutation was observed for hA3G serving as a con-
trol for these studies (Table 1) and no dG-to-dA mutation
was observed when the virus was prepared in the absence
of an APOBEC protein (data not shown). In contrast, the
predominant mutations induced by rabbit A1 that exhib-
ited the most prominent antiviral activity were dC-to-dT
changes (22 and 14 events in 23664 and 24480 bases in
wild-type and Dvif viruses, respectively), which could have
arisen through deamination of unpaired plus-stranded
cDNA or virion RNA. To address the latter possibility,
cell-free virions were puriﬁed and the genomic RNA was
converted to cDNA for pol gene analyses. As can be seen
in Table 2, there was a clear accumulation of dC-to-dT (U
in the template RNA) changes in the RNAs of HIV-1
produced in the presence of rabbit A1 (39 and 51 events
in 9792 and 8976 bases in wild-type and Dvif viruses,
respectively), a frequency that is 4- to 5-fold higher than
those observed in DNA sequencing. Thus, HIV-1 genome
RNA as well as reversetranscribed proviral DNA could be
a substrate for A1-mediated deamination.
The preferential sites of hypermutations induced by
rabbit A1 were also examined (Figure 4). Consistent with
previous observations (23–26), hA3G prefers to edit dC
(marked by an asterisk) in the viral target DNA sequence
C/TCC
 . In constrast, rabbit A1, similar to mouse A3 (27)
and human A3F (13,28,29), show preference for TTC
 
(Figure 4A). These results suggest that rabbit A1 inhibits
HIV-1 infection by a deamination-dependent mechanism
through targeting of proviral DNA sequences that are dif-
ferent from hA3G. Sequence context of the cytidine in viral
RNA sequences mutated by rabbit A1 showed a clear
Table 1. Sequence analysis of reverse transcribed second-strand proviral DNA in the presence of mammalian A1s
A1
hA3G Human Rabbit Rabbit E63A Rabbit E63Q Hamster Mouse Rat
wt Dvif wt Dvif wt Dvif wt Dvif wt Dvif wt Dvif wt Dvif wt Dvif
Clones sequenced 34 36 24 24 58 60 24 23 24 23 34 36 24 24 24 24
Total base pair
sequenced
13872 14688 9792 9792 23664 24480 9792 9384 9792 9384 13872 14688 9792 9792 9792 9792
Clones with G to A 15 22 2 1 13 24 0 0 0 2 1 1 0 6 0 0
Number of G to A
mutations
71 318 5 7 69 118 0 0 0 2 1 1 0 24 0 0
Number of G to A
mutations
per 1 kb
5.12 21.65 0.51 0.71 2.92 4.82 0 0 0 0.21 0.07 0.07 0 2.45 0 0
Clones with C to T 0 0 0 0 20 10 1 0 1 0 3 3 0 5 6 6
Number of C to T
mutations
0 0002 21 42010 3 40 577
Number of C to T
mutations per 1 kb
0 0 0 0 0.93 0.57 0.20 0 0.10 0 0.22 0.27 0 0.51 0.71 0.71
Number of Other
mutations
0 100 1 30000 0 00 000
A 408 bp fragment of HIV-1 pol region was ampliﬁed from reverse transcripts infected with wt or Dvif NL-Luc viruses produced in the presence of
hA3G or mammalian A1s. The number in the clones of each group are shown (wt, wild-type). All mutations are designated using the conventional
plus-strand nomenclature.
Table 2. Sequence analysis of HIV-1 genomic RNA in the presence of mammalian A1s
A1
Mock hA3G Rabbit Rabbit E63A Rabbit E63Q Rat
wt Dvif wt Dvif wt Dvif wt Dvif wt Dvif wt Dvif
Clones sequenced 23 23 21 24 24 22 21 23 24 24 22 24
Total base pair sequenced 9384 9384 8568 9792 9792 8976 8568 9384 9792 9792 8976 9792
Clones with C to T 0 0 0 0 15 17 0 0 0 0 6 13
Number of C to T mutations 0 0 0 0 39 51 0 0 0 0 13 17
Number of C to T mutations
per 1 kb
0 0 0 0 3.98 5.68 0 0 0 0 1.45 1.74
Number of Other mutations 0 2101 0 0 1 1 0 0 0
This experiment was performed as described in the legend for Table 1, except that the genomic RNA of HIV-1 was ampliﬁed (wt, wild-type).
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wild-type and Dvif HIV-1 genomic RNA (Figure 4B). The
cytosine residue within WCW sequences was reported to
be highly conserved as the apoB mRNA-editing site
sequence by A1 protein among divergent of mammalian
species (30). Rabbit A1 deaminated the cytosines in the
genomic RNA but with diﬀerent frequencies; some cyto-
sines were changed at high frequencies, whereas others
were not changed in any of the clones (Figure S4). Taken
together, analysis of these mutations conﬁrms that the
inhibitory eﬀects observed in rabbit A1s were based on,
at least in part, cytosine-deaminating activity on viral
genomic RNA, and the analysis of mutational hot spots
indicated that the molecular mechanisms for editing of
HIV-1 genome RNA and apoB mRNA overlap.
A1s fromsmall animal species exhibitbroad
antilentiviral activity
To assess the breath of A1-mediated antiviral activity,
the activities of these proteins on SIV infectivity
were examined. A single-round assay was used to measure
the infectivity of wild-type and Dvif SIVmac, and SIVagm
luciferase reporter viruses (5), in the presence of A1s.
VSV-G pseudotyped viral supernatants were collected,
normalized for SIV CA p27 and used to infect 293T
cells. As expected, hA3G caused a profound decrease
in infectivity of both wild-type and Dvif SIV viruses
(Figure 5A and C). A1 from rodents were found to be
moderately active, but rabbit A1 signiﬁcantly (4100-
fold) reduced the infectivity of wild-type and Dvif SIV
viruses. In contrast to A1 from small animal species, A1
from human intestine showed no antiviral activity.
Expression of catalytic site mutant forms of rabbit A1
(E63A, E63Q) has little eﬀect on the infectivity of SIV
(Figure 5B and D), suggesting that the deaminase activity
is also important for SIV repressive activities.
To measure the activities of A1 proteins on FIV infec-
tivity, plasmids expressing APOBECs were cotransfected
with an FIV (pFIV-H1/U6-copGFP) genome along
with the packaging pFIV-34N plasmid and pVSV-G.
−2 −1C 1 2
A 18.3% 1.4% 0.0% 28.2% 33.8%
C 40.8% 87.3% 100.0% 33.8% 18.3%
G 0.0% 0.0% 0.0% 2.8% 11.3%
T 40.8% 11.3% 0.0% 35.2% 36.6%
C/T C C T T
hA3G
−2 −1C 1 2
A 20.4% 0.9% 0.0% 23.9% 43.1%
C 23.6% 80.5% 100.0% 29.2% 20.4%
G 0.3% 0.0% 0.0% 0.6% 6.0%
T 55.7% 17.9% 0.0% 46.2% 30.5%
TT CC A
−2 −1C 2 1
A 34.8% 0.0% 0.0% 24.6% 27.5%
C 13.0% 2.9% 100.0% 20.3% 2.9%
G 11.6% 0.0% 0.0% 2.9% 5.8%
T 40.6% 97.1% 0.0% 52.2% 63.8%
TTCTT
Rabbit A1
−2 −1C 12
A 28.0% 0.0% 0.0% 22.0% 38.1%
C 19.5% 14.4% 100.0% 37.3% 12.7%
G 0.0% 0.0% 0.0% 1.7% 6.8%
T 52.5% 85.6% 0.0% 39.0% 42.4%
TT C TT
NL-luc wt
A
B
−2 −1C 2 1
A 30.8% 41.0% 0.0% 51.3% 12.8%
C 35.9% 0.0% 100.0% 10.3% 20.5%
G 15.4% 0.0% 0.0% 5.1% 28.2%
T 17.9% 59.0% 0.0% 33.3% 38.5%
C A/T C A/T T
−2 −1C12
A 31.4% 35.3% 0.0% 54.9% 19.6%
C 47.1% 0.0% 100.0% 0.0% 11.8%
G 9.8% 0.0% 0.0% 0.0% 35.3%
T 11.8% 64.7% 0.0% 45.1% 33.3%
C A/T C A/T G
Rabbit A1
NL-lucwt RNA NL-luc DvifRNA
NL-luc Dvif
Figure 4. Comparison of the preferred sequence context for cytidine deamination by rabbit A1 in ﬁrst strand cDNA and the genomic RNA of wild-
type orDvif viruses. (A) TTC
 T in the HIV-1 minus-strand cDNA was the preferred tetranucleotide target of rabbit A1. Shown are percentages of
each nucleotide found at the  2,  1, +1 and +2 positions relative to the dC residue targeted for deamination (position zero). The consensus DNA
sequence is shown at the bottom of each minitable by bold. (B)W C
 W sequence in the HIV-1 genome was the preferred RNA target of rabbit A1.
Comparison of the preferred sequence observed in the viral genomic RNA produced in the presence of rabbit A1. All of the mutations in HIV-1
genomic RNA aligned with respect to the cytidine (C) targeted for deamination (position zero). The frequency with which each of the four bases
found at positions adjacent to the deaminated C is indicated. The consensus RNA sequence is shown at the bottom of each minitable by bold.
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Figure 5. Inhibition of SIV and FIV infection by A1s. Wild-type and Dvif SIVmac (A and B), wild-type and Dvif SIVagm (C and D) luciferase
reporter viruses pseudotyped were prepared. 293T cells were transfected with 1.5mg of luciferase reporter viruses, 1.0mg of pVSV-G and 0.5mgo f
HA-tagged APOBECs (A and C) or rabbit A1 with catalytic site mutations (B and D). Virus-containing supernatants were normalized for equal p27
content and used for the infection. At 48h postinoculation, virus-induced luciferase activity was measured and presented as described. VSV-G
pseudotyped FIV GFP reporter viruses were produced in 293T cells transfected with 1.5mg of pFIV-H1/copGFP and pFIV-34N, 1.0mg of pVSV-G
and 0.5mg of HA-tagged APOBECs (E) or rabbit A1 with catalytic active site mutations (F). At 48h postinoculation with FIV-GFP virions
normalized for equal RT activity, cells exhibiting GFP ﬂuorescence of target 293T cells were analyzed on ﬂow cytometry. The level of GFP MFI
detected within the GFP-positive windows are indicated. Comparable results were obtained in three additional experiments.
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normalized for RT activity and used to infect 293T cells.
The GFP expression was analyzed by ﬂow cytometry at
48h postinfection. Large proportion of of 293T cells were
positive for GFP expression, with a MFI of 144.7, while in
the cells transduced with hA3G containing FIV virions,
only a few green cells were present, with 5.7-fold lower
MFI of 25.0 (Figure 5E). Interestingly, similar to primate
lentiviruses, the infectivity of FIV was signiﬁcantly
reduced in the presence of rabbit A1, with a 6.2-fold
lower MFI of 23.3. We also detected reduced GFP signals
in the cells transduced with rodent A1-containing virions,
while human and ferret A1s caused minimal reduction in
the number of GFP positive cells (Figure 5E). As seen in
Figure 5F, rabbit A1 with catalytic site mutation E63A
caused a slight decrease in FIV infectivity, but the E63Q
mutation had no eﬀect. Thus, the results using HIV-1,
SIVmac, SIVagm and FIV reporter viruses combined sug-
gest that the A1s from small animal species have a rela-
tively broad lentivirus restriction potential that is mainly
mediated through deaminase-dependent mechanism.
A1s affectMLV virioninfectivity
Evidence is mounting that some APOBEC proteins can
target a variety of retroviral substrates, such as various
oncovirus and spumavirus. The A3 orthologs from artio-
dactyls; cattle, pigs and sheep, as well as hAB and hA3G
have been reported to exert antiviral activity on MLV
(6,13,23,24). These ﬁndings suggest that A3s in artiodac-
tyls could function as barriers of cross-subspecies trans-
mission of MLV from mice. Interestingly, this simple
oncovirus is resistant to the mouse A3, explaining the
absence of a Vif-like activity in MLV (27,31), but the
underlying mechanism is currently unknown (32).
Therefore, we examined whether the A1s expressed in
small animal species aﬀect MLV infection. MLV-based
reporter viruses were produced by transient transfection
of pFB-Luc, encoding the luciferase gene, into the MLV
packaging cell line GP293 with pVSV-G, in the presence
of APOBEC proteins. As shown in Figure 6A, hA3G was
able to restrict the infectivity of MLV, consistent with
previous reports (13,23,24). Interestingly, MLV infectivity
was inhibited  7-fold by rabbit A1, while A1s from other
mammalian species had none or only moderate eﬀect.
Similar results were obtained with another murine retro-
viral vector, pFB-hrGFP (data not shown). Deaminase-
defective rabbit A1s retained only partial antiviral activity
(Figure 6B) despite comparable levels of MLV virion
incorporation (Figure 6C). These data suggest that A1
from small animal species functions as potential barriers
of cross-species transmission of this gammmaretroviruses
from mice.
DISCUSSION
In this study, we showed that single domain cytidine dea-
minase A1 from rodents (mouse, rat and hamster) and
largomorphs (rabbit) are capable of inhibiting the infec-
tivity of various lentiviruses in tissue culture models. A
rank order in anti-HIV potency was seen, with rabbit
A1 showing the greatest activity. The ﬁnding of more
eﬃcient virion incorporation of rabbit as compared to
other small animal species A1 proteins may be a contri-
buting factor. Catalytic site mutant analysis suggested a
deaminase-dependent restriction mechanism, with geno-
mic RNA as well as reversetranscribed proviral DNA ser-
ving as substrates for A1-mediated deamination.
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Figure 6. Inhibition of MLV infection by A1s. (A and B) MLV packa-
ging cell line GP293 were transfected with 1.5mg of luciferase pFB-Luc
reporter plasmids, 1.0mg of pVSV-G and 0.5mg of HA-tagged
APOBECs or rabbit A1 with catalytic site mutations. Virus-containing
supernatants were normalized for equal MLV p30 CA content and used
for the infection of the MDTF cells. Virus-induced intracellular lucifer-
ase activity was measured and presented as described. (C) Rabbit A1
proteins are encapsidated into MLV virions. After transfection, released
virion was collected by ultracentrifugation, while the producer cells
were collected and lyzed. The cells and virion lysates were then sub-
jected to Western analysis using antibodies speciﬁc for the HA tag and
MLV Gag CA. An immunoblot probed with anti-b-actin antibody of
the proteins present in the cell lysates is also shown. While only the
immunoblot of p30 CA performed with the disrupted virions is pre-
sented, closely similar results were also obtained using the cell lysates
(data not shown).
6868 Nucleic Acids Research, 2008, Vol. 36, No. 21A clear accumulation of C-T changes in the genomic
RNAs of HIV-1 produced in the presence of rabbit A1
was observed, with G-A changes in the proviral DNA.
Furthermore, expression of catalytic site mutant forms of
rabbit A1 has little eﬀect on the viral infectivity, supporting
the importance of the deaminase activity for these repres-
sive activities. Cytidine deaminase-defective A3 mutants
have been shown to exhibit signiﬁcant antiviral activity
(33), implying that antiviral and deaminase activities can
be uncoupled. Further evidence in support of editing-inde-
pendent antiviral mechanism comes from studies on the
enzymatically inactive, high-molecular mass complex of
hA3G (34) as well as on the antiviral activity against hepa-
titis B virus (HBV) (35). Nevertheless, more recent studies
using deaminase-defective A3 mutants show that eﬃcient
inhibition of HIV-1 or retroelements requires catalytically
active A3 (36,37). In this regard, although deaminase-
defective rabbit A1 mutants were shown to inhibit various
lentivirus and MLV, these antiviral activities were signiﬁ-
cantly lower than those seen with wild-type A1. The sup-
pressive activity of A1, therefore, is principally associated
with its cytidine deaminase activity.
We demonstrated that the molecular mechanism for A1
editing of the HIV-1 genomic RNA and apoB mRNA
overlapped. The C to U editing of apoB mRNA is
shown to be a nuclear event (38), mediated by a complex
composed of A1 homodimer and an A1 complementation
factor (ACF) (39–41). Expression of ACF mRNA in cells
such as Caco-2, a human colon cancer-derived cell line
demonstrated to edit endogenous apoB mRNA has been
documented (42). However, mRNA for ACF could not be
detected by RT-PCR in 293T cells used for retorovirus
production in this study (Supplementary Figure S5).
Thus, the site(s) in virus-producing cells (e.g. nucleus,
cytoplasm or both) where the deamination of HIV-1 geno-
mic RNA takes place remains to be identiﬁed, and further
experiments are needed to fully understand the role of
ACF in the editing of retroviral genome observed in the
present study.
In our study, A1s were expressed using both a chick
b-actin (CAG) and a cytomegalovirus promoter-driven
expression vector, and the concentration of A1s required
to mediate antiviral activity was titrated carefully. We
found that only 0.05mg of rabbit A1 was required to
achieve signiﬁcant inhibition against HIV-1 (Figure 2B).
Moreover, the antiviral activity of rabbit A1 appeared to
be more potent than hA3G (Supplementary Figure S1),
and this is unlikely to be explained by diﬀerences in virion
incorporation of the two enzymes (Figure 2D). Taken
together, the data suggest that antiretroviral activities of
A1s observed in this study were not solely due to using
overexpressed protein systems.
We found that human A1 exhibited no antiretroviral
activity, consistent with reports of others (12,13,29,43).
A1 from hominoids, therefore, appears to exclusively
mediate the C to U editing of apoB mRNA, giving rise
to two proteins with diﬀerent sizes in the gastrointesitinal
tissues that function in lipid transport and metabolism. As
there have been no reports thus far of lentivirus infection
in rodents, the antiviral activity of A1 proteins in rodents
seen against HIV, SIV and FIV are also unlikely to have
evolved originally to restrict infection of these lentiviruses.
Nevertheless, the ﬁnding that rabbit A1 can restrict MLV
raises the possibility that A1s from small animals species
evolved to restrict cross-subspecies transmission of onco-
viruses from mice. Furthermore, endogenous lentivirus of
rabbits has recently been described (44), lending biological
signiﬁcance to the antilentiviral activity in lagomorphs
reported here. Further studies of the antiviral activities
of A1 proteins from other members of the placentalia
super-order of Laurasiatheria; cetartiodactyla (cow, pig,
sheep) and carnivore (cat) will be required to fully under-
stand the complex evolutionary history of APOBEC genes
as an intrinsic resistance mechanism against retroelements.
HIV-1 exhibits a highly restricted host cell tropism. The
identiﬁcation of chemokine receptors as entry cofactors
with human CD4 raises the possibility that small animal
species, in particular, rodents could be engineered to
express these molecules, thereby rendering them able to
support a productive HIV-1 infection. However, HIV-1
replication in rodents (45–47) and rabbits (48,49) expres-
sing human versions of the HIV-1 receptors appeared to
be limited and variable. Our ﬁndings with A1 suggest that
this enzyme may be partly responsible for the ineﬃcient
replication of HIV-1 observed in rabbit as well as rodent
cells. Blocking of antiviral A1 function by RNA interfer-
ence in cells from small animal species should verify
whether A1 acts as an intrinsic resistance factor. Further
understanding of these species-nonspeciﬁc repressive
activities to HIV-1 replication at the late phase, in conju-
gation with the early block owing to the diﬀerent classes
of activities, such as TRIM5a (50,51), may suggest
approaches to the development of small animal models
of HIV-1 infection.
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